TRAF5 Antibody (B-6): sc-271145

TRAF5 Antibody (B-6) is a mouse monoclonal IgG1 antibody that detects TRAF5 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TRAF5 is a crucial member of the TNF receptor-associated factor (TRAF) protein family, which plays a significant role in mediating signal transduction from the tumor necrosis factor receptor superfamily. TRAF5 is primarily located in the cytoplasm, where TRAF5 forms complexes with various receptors, including CD40, CD27, and CD30, facilitating essential signaling pathways that lead to the activation of NF-kappa B and the regulation of cell survival. Proper functioning of TRAF5 is vital for immune responses, particularly in processes like osteoclastogenesis, where TRAF5 influences the differentiation and activation of osteoclasts, cells responsible for bone resorption. Additionally, TRAF5 undergoes post-translational modifications, such as ubiquitination, which can affect stability and activity, further underscoring TRAF5′s importance in cellular signaling and immune regulation. With two alternatively spliced transcript variants encoding the same protein, TRAF5 continues to be a focal point of research, highlighting TRAF5′s diverse roles in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TRAF5 Antibody (B-6) References:

1. TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction.  |  Kimura, M., et al. 2018. Int Immunol. 30: 291-299. PMID: 29668931
2. LINC00467 promotes cell proliferation and metastasis by binding with IGF2BP3 to enhance the mRNA stability of TRAF5 in hepatocellular carcinoma.  |  Jiang, W., et al. 2020. J Gene Med. 22: e3134. PMID: 31656043
3. LncRNA CDKN2B-AS1 contributes to tumorigenesis and chemoresistance in pediatric T-cell acute lymphoblastic leukemia through miR-335-3p/TRAF5 axis.  |  Chen, L., et al. 2020. Anticancer Drugs.. PMID: 32976214
4. Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.  |  Ma, Y., et al. 2020. J Cell Mol Med. 24: 12933-12944. PMID: 33048450
5. Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5.  |  Ding, G., et al. 2021. Cancer Cell Int. 21: 179. PMID: 33752668
6. LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b.  |  Zhang, F., et al. 2022. Mol Med. 28: 2. PMID: 34983361
7. Bioinformatics Analysis of miRNAs Targeting TRAF5 in DLBCL Involving in NF-κB Signaling Pathway and Affecting the Apoptosis and Signal Transduction.  |  Li, C., et al. 2022. Genet Res (Camb). 2022: 3222253. PMID: 36619898
8. PCSK9 inhibitor attenuates atherosclerosis by regulating SNHG16/EZH2/TRAF5-mediated VSMC proliferation, migration, and foam cell formation.  |  Liu, Y., et al. 2023. Cell Biol Int. 47: 1267-1280. PMID: 37017413
9. TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor.  |  Nakano, H., et al. 1996. J Biol Chem. 271: 14661-4. PMID: 8663299
10. Human TNF receptor-associated factor 5 (TRAF5): cDNA cloning, expression and assignment of the TRAF5 gene to chromosome 1q32.  |  Nakano, H., et al. 1997. Genomics. 42: 26-32. PMID: 9177772

The preferred TRAF5 antibody is TRAF5 Antibody (E-4): sc-74502.